Sebastian Marschner

We don’t have enough information about this author to calculate their statistics. If you think this is an error let us know.
Learn More
Nivolumab is a feasible therapy option in patients with advanced non-small cell lung cancer (NSCLC) who progress on first-line treatment. However, there is limited information about an overlapping toxicity of PD-1 inhibitors when administered following thoracic radiotherapy (TRT). Three of 25 patients with advanced NSCLC were treated with palliative or(More)
  • 1